Serum amyloid A in uremic HDL promotes inflammation

Journal of the American Society of Nephrology

Volumn 23, Issue 5, 2012, Pages 934-947

  Weichhart, Thomas ^a   Kopecky, Chantal ^a   Kubicek, Markus ^a   Haidinger, Michael ^a   Döller, Dominik ^a   Katholnig, Karl ^a   Suarna, Cacang ^b   Eller, Philipp ^c   Tölle, Markus ^d   Gerner, Christopher ^a   Zlabinger, Gerhard J ^a   Van Der Giet, Markus ^d   Hörl, Walter H ^a   Stocker, Roland ^b   Säemann, Marcus D ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 MICROGLOBULIN; APOLIPOPROTEIN C2; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; COMPLEMENT FACTOR D; HEME; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 6; PIGMENT EPITHELIUM DERIVED FACTOR; SERUM AMYLOID A; SURFACTANT PROTEIN B; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; ULINASTATIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; INFLAMMATION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; ONCOGENE SRC; OXIDATION; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEOMICS; UREMIA;

EID: 84860629777     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2011070668     Document Type: Article

References (79)

1. Shoham DA, Vupputuri S, Kshirsagar AV: Chronic kidney disease and life course socioeconomic status: A review. Adv Chronic Kidney Dis 12: 56-63, 2005 (Pubitemid 40255604)
2. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX: Chronic kidney disease and mortality risk: A systematic review. J Am Soc Nephrol 17: 2034-2047, 2006 (Pubitemid 44036188)
3. Goodkin DA, Bragg-Gresham JL, Koenig KG, Wolfe RA, Akiba T, Andreucci VE, Saito A, Rayner HC, Kurokawa K, Port FK, Held PJ, Young EW: Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: The Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 14: 3270-3277, 2003 (Pubitemid 37509303)
4. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004
5. Kwan BC, Kronenberg F, Beddhu S, Cheung AK: Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol 18: 1246-1261, 2007 (Pubitemid 46536911)
6. Chan DT, Irish AB, Dogra GK, Watts GF: Dyslipidaemia and cardiorenal disease: Mechanisms, therapeutic opportunities and clinical trials. Atherosclerosis 196: 823-834, 2008
7. Muntner P, He J, Astor BC, Folsom AR, Coresh J: Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: Results from the atherosclerosis risk in communities study. J Am Soc Nephrol 16: 529-538, 2005 (Pubitemid 41725151)
8. Kalantar-Zadeh K, Block G, McAllister CJ, Humphreys MH, Kopple JD: Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr 80: 299-307, 2004 (Pubitemid 41080002)
9. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39[Suppl 1]: S1-S266, 2002
10. Vaziri ND: Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 290: F262-F272, 2006
11. Vaziri ND, Navab M, Fogelman AM: HDL metabolism and activity in chronic kidney disease. Nat Rev Nephrol 6: 287-296, 2010
12. deGoma EM, deGoma RL, Rader DJ: Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol 51: 2199-2211, 2008
13. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM: Antiinflammatory properties of HDL. Circ Res 95: 764-772, 2004 (Pubitemid 39390578)
14. Säemann MD, Poglitsch M, Kopecky C, Haidinger M, Hörl WH, Weichhart T: The versatility of HDL: A crucial anti-inflammatory regulator. Eur J Clin Invest 40: 1131-1143, 2010
15. van der Giet M, Tölle M: Why HDL cholesterol is 'good cholesterol.'Eur J Clin Invest 34: 247-248, 2004
16. Ansell BJ, Fonarow GC, Fogelman AM: The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol 18: 427-434, 2007 (Pubitemid 47051922)
17. Gordon SM, Hofmann S, Askew DS, Davidson WS: High density lipoprotein: It's not just about lipid transport anymore. Trends Endocrinol Metab 22: 9-15, 2011
18. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, Vahabzadeh K, Hama S, Hough G, Kamranpour N, Berliner JA, Lusis AJ, Fogelman AM: The oxidation hypothesis of atherogenesis: The role of oxidized phospholipids and HDL. J Lipid Res 45: 993-1007, 2004 (Pubitemid 38679495)
19. Bonnefont-Rousselot D, Thérond P, Beaudeux JL, Peynet J, Legrand A, Delattre J: High density lipoproteins (HDL) and the oxidative hypothesis of atherosclerosis. Clin Chem Lab Med 37: 939-948, 1999 (Pubitemid 30011571)
20. Francis GA: High density lipoprotein oxidation: in vitro susceptibility and potential in vivo consequences. Biochim Biophys Acta 1483: 217-235, 2000
21. Marsche G, Furtmüller PG, Obinger C, Sattler W, Malle E: Hypochlorite-modified high-density lipoprotein acts as a sink for myeloperoxidase in vitro. Cardiovasc Res 79: 187-194, 2008 (Pubitemid 351881925)
22. Suc I, Brunet S, Mitchell G, Rivard GE, Levy E: Oxidative tyrosylation of high density lipoproteins impairs cholesterol efflux from mouse J774 macrophages: Role of scavenger receptors, classes A and B. J Cell Sci 116: 89-99, 2003 (Pubitemid 36113968)
23. Valiyaveettil M, Kar N, Ashraf MZ, Byzova TV, Febbraio M, Podrez EA: Oxidized high-density lipoprotein inhibits platelet activation and aggregation via scavenger receptor BI. Blood 111: 1962-1971, 2008 (Pubitemid 351451506)
24. Upston JM, Niu X, Brown AJ, Mashima R, Wang H, Senthilmohan R, Kettle AJ, Dean RT, Stocker R: Disease stage-dependent accumulation of lipid and protein oxidation products in human atherosclerosis. Am J Pathol 160: 701-710, 2002 (Pubitemid 34160348)
25. Pankhurst G, Wang XL, Wilcken DE, Baernthaler G, Panzenböck U, Raftery M, Stocker R: Characterization of specifically oxidized apolipoproteins in mildly oxidized high density lipoprotein. J Lipid Res 44: 349-355, 2003 (Pubitemid 37287778)
26. Bergt C, Pennathur S, Fu X, Byun J, O'Brien K, McDonald TO, Singh P, Anantharamaiah GM, Chait A, Brunzell J, Geary RL, Oram JF, Heinecke JW: The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci USA 101: 13032-13037, 2004 (Pubitemid 39167578)
27. Honda H, Ueda M, Kojima S, Mashiba S, Suzuki H, Hosaka N, Hirai Y, Nakamura M, Nagai H, Kato N, Mukai M, Watanabe M, Takahashi K, Shishido K, Akizawa T: Oxidized high-density lipoprotein is associated with protein-energy wasting in maintenance hemodialysis patients. Clin J Am Soc Nephrol 5: 1021-1028, 2010
28. Massy ZA, Stenvinkel P, Drueke TB: The role of oxidative stress in chronic kidney disease. Semin Dial 22: 405-408, 2009
29. Kao MP, Ang DS, Pall A, Struthers AD: Oxidative stress in renal dysfunction: Mechanisms, clinical sequelae and therapeutic options. J Hum Hypertens 24: 1-8, 2010
30. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62: 1524-1538, 2002 (Pubitemid 35286260)
31. Kilpatrick RD, McAllister CJ, Kovesdy CP, Derose SF, Kopple JD, Kalantar-Zadeh K: Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 18: 293-303, 2007 (Pubitemid 46053442)
32. Kalantar-Zadeh K, Kopple JD, Kamranpour N, Fogelman AM, Navab M: HDL-inflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int 72: 1149-1156, 2007 (Pubitemid 47609043)
33. Vaziri ND, Moradi H, Pahl MV, Fogelman AM, Navab M: In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. Kidney Int 76: 437-444, 2009
34. Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G Cholesterol and Recurrent Events (CARE) Trial Investigators: Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 68: 237-245, 2005 (Pubitemid 43181381)
35. Tonelli M, Pfeffer MA: Kidney disease and cardiovascular risk. Annu Rev Med 58: 123-139, 2007 (Pubitemid 46706505)
36. Moradi H, Pahl MV, Elahimehr R, Vaziri ND: Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Transl Res 153: 77-85, 2009
37. Kaysen GA, Kumar V: Inflammation in ESRD: Causes and potential consequences. J Ren Nutr 13: 158-160, 2003 (Pubitemid 38368776)
38. Karlsson H, Leanderson P, Tagesson C, Lindahl M: Lipoproteomics I: Mapping of proteins in low-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 5: 551-565, 2005 (Pubitemid 40262072)
39. Rezaee F, Casetta B, Levels JH, Speijer D, Meijers JC: Proteomic analysis of high-density lipoprotein. Proteomics 6: 721-730, 2006 (Pubitemid 43208050)
40. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, Byun J, Vuletic S, Kassim S, Singh P, Chea H, Knopp RH, Brunzell J, Geary R, Chait A, Zhao XQ, Elkon K, Marcovina S, Ridker P, Oram JF, Heinecke JW: Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 117: 746-756, 2007 (Pubitemid 46348533)
41. Heller M, Schlappritzi E, Stalder D, Nuoffer JM, Haeberli A: Compositional protein analysis of high density lipoproteins in hypercholesterolemia by shotgun LC-MS/MS and probabilistic peptide scoring. Mol Cell Proteomics 6: 1059-1072, 2007 (Pubitemid 47019407)
42. Green PS, Vaisar T, Pennathur S, Kulstad JJ, Moore AB, Marcovina S, Brunzell J, Knopp RH, Zhao XQ, Heinecke JW: Combined statin and niacin therapy remodels the high-density lipoprotein proteome. Circulation 118: 1259-1267, 2008
43. Gordon SM, Deng J, Lu LJ, Davidson WS: Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatography. J Proteome Res 9: 5239-5249, 2010
44. Gordon S, Durairaj A, Lu JL, Davidson WS: High-density lipoprotein proteomics: Identifying new drug targets and biomarkers by understanding functionality. Curr Cardiovasc Risk Rep 4: 1-8, 2010
45. Suzuki M, Pritchard DK, Becker L, Hoofnagle AN, Tanimura N, Bammler TK, Beyer RP, Bumgarner R, Vaisar T, de Beer MC, de Beer FC, Miyake K, Oram JF, Heinecke JW: High-density lipoprotein suppresses the type I interferon response, a family of potent antiviral immunoregulators, inmacrophages challengedwith lipopolysaccharide. Circulation 122: 1919-1927, 2010
46. Havel RJ, Eder HA, Bragdon JH: The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34: 1345-1353, 1955
47. Garner B, Witting PK, Waldeck AR, Christison JK, Raftery M, Stocker R: Oxidation of high density lipoproteins. I. Formation of methionine sulfoxide in apolipoproteins AI and AII is an early event that accompanies lipid peroxidation and can be enhanced by alpha-tocopherol. J Biol Chem273: 6080-6087, 1998 (Pubitemid 28144687)
48. Shao B, Oda MN, Bergt C, Fu X, Green PS, Brot N, Oram JF, Heinecke JW: Myeloperoxidase impairs ABCA1-dependent cholesterol efflux through methionine oxidation and site-specific tyrosine chlorination of apolipoprotein A-I. J Biol Chem 281: 9001-9004, 2006 (Pubitemid 43864611)
49. Shao B, Cavigiolio G, Brot N, Oda MN, Heinecke JW: Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I. Proc Natl Acad Sci USA 105: 12224-12229, 2008
50. Nagy E, Eaton JW, Jeney V, Soares MP, Varga Z, Galajda Z, Szentmiklósi J, Méhes G, Csonka T, Smith A, Vercellotti GM, Balla G, Balla J: Red cells, hemoglobin, heme, iron, and atherogenesis. Arterioscler Thromb Vasc Biol 30: 1347-1353, 2010
51. Watanabe J, Grijalva V, Hama S, Barbour K, Berger FG, Navab M, Fogelman AM, Reddy ST: Hemoglobin and its scavenger protein haptoglobin associate with apoA-1-containing particles and influence the inflammatory properties and function of high density lipoprotein. J Biol Chem284: 18292-18301, 2009
52. Boes E, Fliser D, Ritz E, König P, Lhotta K, Mann JF, Müller GA, Neyer U, Riegel W, Riegler P, Kronenberg F: Apolipoprotein A-IV predicts progression of chronic kidney disease: The mild to moderate kidney disease study. J Am Soc Nephrol 17: 528-536, 2006
53. Hirano T, Nohtomi K, Nakanishi N, Watanabe T, Hyodo T, Taira T: Ezetimibe decreases serum amyloid A levels in HDL3 in hemodialysis patients. Clin Nephrol 74: 282-287, 2010
54. De Pasquale CG, Arnolda LF, Doyle IR, Aylward PE, Chew DP, Bersten AD: Plasma surfactant protein-B: A novel biomarker in chronic heart failure. Circulation 110: 1091-1096, 2004 (Pubitemid 39319007)
55. Kalantar-Zadeh K, Regidor DL, Kovesdy CP, Van Wyck D, Bunnapradist S, Horwich TB, Fonarow GC: Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. Circulation 119: 671-679, 2009
56. Whitehead AS, de Beer MC, Steel DM, Rits M, Lelias JM, Lane WS, de Beer FC: Identification of novel members of the serum amyloid A protein superfamily as constitutive apolipoproteins of high density lipoprotein. J Biol Chem267: 3862-3867, 1992
57. Kaysen GA: Dyslipidemia in chronic kidney disease: Causes and consequences. Kidney Int 70: S55-S58, 2006
58. Tsirpanlis G, Bagos P, Ioannou D, Bleta A, Marinou I, Lagouranis A, Chatzipanagiotou S, Nicolaou C: The variability and accurate assessment of microinflammation in haemodialysis patients. Nephrol Dial Transplant 19: 150-157, 2004 (Pubitemid 38072626)
59. Lee HY, Kim MK, Park KS, Shin EH, Jo SH, Kim SD, Jo EJ, Lee YN, Lee C, Baek SH, Bae YS: Serumamyloid A induces contrary immune responses via formyl peptide receptor-like 1 in human monocytes. Mol Pharmacol 70: 241-248, 2006
60. Baranova IN, Bocharov AV, Vishnyakova TG, Kurlander R, Chen Z, Fu D, Arias IM, Csako G, Patterson AP, Eggerman TL: CD36 is a novel serum amyloid A (SAA) receptor mediating SAA binding and SAA-induced signaling in human and rodent cells. J Biol Chem 285: 8492-8506, 2010
61. He R, Sang H, Ye RD: Serumamyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R. Blood 101: 1572-1581, 2003 (Pubitemid 36182537)
62. Niemi K, Teirilä L, Lappalainen J, Rajamäki K, Baumann MH, Öörni K, Wolff H, Kovanen PT, Matikainen S, Eklund KK: Serum amyloid A activates the NLRP3 inflammasome via P2X7 receptor and a cathepsin B-sensitive pathway. J Immunol 186: 6119-6128, 2011
63. Cheng N, He R, Tian J, Ye PP, Ye RD: Cutting edge: TLR2 is a functional receptor for acute-phase serum amyloid A. J Immunol 181: 22-26, 2008
64. Sandri S, Rodriguez D, Gomes E, Monteiro HP, Russo M, Campa A: Is serum amyloid A an endogenous TLR4 agonist? J Leukoc Biol 83: 1174-1180, 2008 (Pubitemid 351960349)
65. Song C, Shen Y, Yamen E, Hsu K, Yan W, Witting PK, Geczy CL, Freedman SB: Serum amyloid A may potentiate prothrombotic and proinflammatory events in acute coronary syndromes. Atherosclerosis 202: 596-604, 2009
66. Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, Schmitt D, Fu X, Thomson L, Fox PL, Ischiropoulos H, Smith JD, Kinter M, Hazen SL: Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 114: 529-541, 2004 (Pubitemid 39572103)
67. Bowry VW, Stanley KK, Stocker R: High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci USA 89: 10316-10320, 1992
68. Weichhart T, Costantino G, Poglitsch M, Rosner M, Zeyda M, Stuhlmeier KM, Kolbe T, Stulnig TM, Hörl WH, Hengstschläger M, Müller M, Säemann MD: The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 29: 565-577, 2008
69. Ruppert C, Bagheri A, Markart P, Schmidt R, Seeger W, Günther A: Liver carboxylesterase cleaves surfactant protein (SP-) B and promotes surfactant subtype conversion. Biochem Biophys Res Commun 348: 1449-1454, 2006 (Pubitemid 44291360)
70. Haidinger M, Poglitsch M, Geyeregger R, Kasturi S, Zeyda M, Zlabinger GJ, Pulendran B, Horl WH, Saemann MD, Weichhart T: A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation. J Immunol 185: 3919-3931, 2010
71. Gundacker NC, Haudek VJ, Wimmer H, Slany A, Griss J, Bochkov V, Zielinski C, Wagner O, Stöckl J, Gerner C: Cytoplasmic proteome and secretome profiles of differently stimulated human dendritic cells. J Proteome Res 8: 2799-2811, 2009
72. Wimmer H, Gundacker NC, Griss J, Haudek VJ, Stättner S, Mohr T, Zwickl H, Paulitschke V, Baron DM, Trittner W, Kubicek M, Bayer E, Slany A, Gerner C: Introducing the CPL/MUW proteome database: Interpretation of human liver and liver cancer proteome profiles by referring to isolated primary cells. Electrophoresis 30: 2076-2089, 2009
73. Slany A, Haudek VJ, Zwickl H, Gundacker NC, Grusch M, Weiss TS, Seir K, Rodgarkia-Dara C, Hellerbrand C, Gerner C: Cell characterization by proteome profiling applied to primary hepatocytes and hepatocyte cell lines Hep-G2 and Hep-3B. J Proteome Res 9: 6-21, 2010
74. Zhang B, VerBerkmoes NC, Langston MA, Uberbacher E, Hettich RL, Samatova NF: Detecting differential and correlated protein expression in label-free shotgun proteomics. J Proteome Res 5: 2909-2918, 2006 (Pubitemid 44749209)
75. Wang XS, Shao B, Oda MN, Heinecke JW, Mahler S, Stocker R: A sensitive and specific ELISA detects methionine sulfoxide-containing apolipoprotein A-I in HDL. J Lipid Res 50: 586-594, 2009
76. Davidson WS, Silva RA, Chantepie S, Lagor WR, Chapman MJ, Kontush A: Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: Relevance to antioxidative function. Arterioscler Thromb Vasc Biol 29: 870-876, 2009
77. Vaisar T, Mayer P, Nilsson E, Zhao XQ, Knopp R, Prazen BJ: HDL in humans with cardiovascular disease exhibits a proteomic signature. Clin Chim Acta 411: 972-979, 2010
78. Bin LH, Nielson LD, Liu X, Mason RJ, Shu HB: Identification of uteroglobin-related protein 1 and macrophage scavenger receptor with collagenous structure as a lung-specific ligand-receptor pair. J Immunol 171: 924-930, 2003 (Pubitemid 36871406)
79. Meek RL, Eriksen N, Benditt EP: Murine serum amyloid A3 is a high density apolipoprotein and is secreted by macrophages. Proc Natl Acad Sci USA 89: 7949-7952, 1992